Collectively, these data indicate that treatment with the PERK inhibitor GSK2656157 ameliorates viral myocarditis by promoting cardiac antiviral function, attenuating inflammation, reducing cardiac ER stress and apoptosis, and reducing immunosuppressive mMDSC to enhance functions of antiviral CD8 T cells in vivo. The gene discussed is CD8A; the disease is viral myocarditis.